C12N2740/15071

RETARGETED RETROVIRAL VECTORS AND COMPOSITIONS OR METHODS OF USE THEREOF

The invention features pseudotyped viral particles (e.g., lentiviral or gammaretroviral particles) and compositions and methods of use thereof, where the viral particles comprise a VHH domain.

Compositions and Methods for Treatment of Cancer

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

GENE THERAPY BASED ADMINISTRATION OF LENTIVIRUS VECTOR FOR TREATING HEMOGLOBINOPATHIES
20240350664 · 2024-10-24 ·

The invention provides persistent expression of -globin gene by using cell and/or gene therapy based administration of nucleotide sequence encoding -globin gene to treat thalassemia and sickle cell anemia. Lentivirus (LV) based viral vector system containing an expression cassette of -globin gene. Whereas, the lentivirus particle is packed with genes expressing functional -globin gene in erythroid cell lineage specifically.

Replication-competent VSV-HIV Env vaccines

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Elimination of immune responses to viral vectors

The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.

CMV glycoproteins and recombinant vectors

Disclosed herein are recombinant CMV vectors which may comprise a heterologous antigen that can repeatedly infect an organism while inducing a CD8+ T cell response to immunodominant epitopes of the heterologous antigen. The CMV vector may comprise a deleterious mutation in the US11 glycoprotein or a homolog thereof.

Compositions and Methods for Treatment of Cancer

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

IL-12 IMMUNOTHERAPY FOR CANCER
20170136072 · 2017-05-18 ·

Compositions and methods far delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

REPLICATION-COMPETENT VSV-HIV ENV VACCINES
20170095551 · 2017-04-06 ·

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

Compositions and methods for treatment of cancer

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.